BioTime (NYSEMKT: BTX), a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies.
BTX’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis.
BTX also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products.
Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia.
BioTime, Inc. was founded in 1990 and is based in Alameda, California.
August 20, 2019
RegMed Investors’ (RMi) pre-open: skim if you can trim, buy if it will fly and sell if compelled!
August 19, 2019
RegMed Investors’ (RMi) closing bell: the sector rallied
August 19, 2019
RegMed Investors’ (RMi) pre-open: futures are jumping
August 16, 2019
RegMed Investors’ (RMi) closing bell: a whacky week as the volatility index of 19.13, -2.71 or -12.80%
August 8, 2019
RegMed Investors’ (RMi) closing bell: the daily dose of share pricing
August 7, 2019
RegMed Investors’ (RMi) closing bell: the share pricing merry-go-round keeps spinning
August 5, 2019
RegMed Investors’ (RMi) closing bell: another wipe-out of sector value
August 5, 2019
Regenerative Medicine Earnings Scorecard - Q2/19 - to date
August 5, 2019
RegMed Investors’ (RMi) pre-open: global market selloff as Chinese weaken their currency
August 2, 2019
RegMed Investors’ (RMi) closing bell: the session and the week’s review
35 companies, 1 interpreter!
Insight, foresight and recommendation
BioTime, Inc. (BTX) -- open 1/1/18 at $2.29, rolled to $3.05 by 2/1 but, has been slipping to $2.60 on 2/16. Needs news and differentiation of the story and the definition of their multiple markets addressed ... also rolls with news yet a complacent stock ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.